Establishment Labs Holdings Inc. (ESTA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 85 | 127 | 162 | 165 | 166 | 211 | 246 | 270 |
| Operating profit | $m | -39 | -19 | ||||||
| Net profit | $m | -38 | -41 | -75 | -79 | -85 | -51 | -39 | -36 |
| EPS reported | $ | -1.72 | -1.31 | ||||||
| Operating cashflow per share | $ | -1.72 | -1.09 | ||||||
| Capex per share | $ | 0.23 | 0.31 | ||||||
| FCF per share | $ | -1.94 | -1.40 | ||||||
| Free cash flow | $m | -58 | -42 | ||||||
| Net debt | $m | 184 | 191 | ||||||
| Book value equity | $m | 24 | 22 | ||||||
| Book value per share | $ | 0.79 | 0.72 | ||||||
| Number of shares | m | 29.62 | 30.12 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 91.68 | 99.91 | ||||||
| P/S LTM | x | 10.23 | 8.78 | ||||||
| P/FCF LTM | x | -37.47 | -51.33 | ||||||
| EV/EBITDA LTM | x | -105.32 | -350.73 | ||||||
| EV/Sales LTM | x | 11.12 | 10.30 | ||||||
| Earnings Yield LTM | % | -2.37% | -1.62% | ||||||
| FCF Yield | % | -2.67% | -1.95% | ||||||
| Quality | |||||||||
| ROE | % | -216.86% | -203.88% | ||||||
| ROIC | % | -11.87% | -5.35% | ||||||
| Operating margin | % | -18.48% | -7.63% | ||||||
| Gross margin | % | +69.32% | +70.49% | ||||||
| FCF/Sales | % | -27.29% | -17.11% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +27.14% | +48.06% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.22 | -0.16 | ||||||
| Net Debt/EBITDA | x | -8.47 | -28.76 | ||||||
| EBIT/Net interest | x | -1.54 | -0.68 | ||||||
| Net debt/market cap | % | +12.04% | +11.19% | ||||||
| Net debt/Equity | x | 7.83 | 8.82 | ||||||
| Gross debt/equity | x | 11.23 | 12.20 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Establishment Labs Holdings Inc. (ESTA)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free